Filing Analysis
Cartesian Therapeutics reported the voting results from its 2026 Annual Meeting of Stockholders held on June 12, 2026. Shareholders elected three Class I directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent auditor.
🚩 Red Flags
- Significant 'Withheld' votes for directors Michael Singer (8.08M) and Patrick Zenner (7.66M), suggesting some shareholder dissatisfaction despite their election.
📋 Key Facts
- Annual Meeting held on June 12, 2026, with 82.42% of outstanding common stock represented (24,151,536 shares).
- Three Class I Directors were elected: Michael Singer, M.D., Ph.D., Timothy A. Springer, Ph.D., and Patrick Zenner, M.B.A.
- Executive compensation was approved on a non-binding advisory basis with 13,659,709 votes FOR and 136,217 votes AGAINST.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma Co. to develop in vivo CAR-T therapies for autoimmune diseases.
📋 Key Facts
- Agreement entered into with WestGene Biopharma Co. on June 9, 2026.
- Focus of the partnership is the development of novel in vivo chimeric antigen receptor T-cell (CAR-T) therapies.
- Target therapeutic area is autoimmune diseases.
Cartesian Therapeutics entered into a senior secured loan agreement for up to $150 million, while simultaneously announcing the resignation of its Chief Medical Officer, Dr. Milos Miljkovic.
🚩 Red Flags
- Multiple 8-K items in a single filing (1.01, 2.03, 3.02, 5.02, 7.01), which often indicates a cluster of material events.
- High-interest debt with restrictive covenants including a revenue floor ($40M) that may be aggressive for a clinical-stage company.
- Departure of the Chief Medical Officer (CMO) coinciding with a major financing event.
- Debt is secured by substantially all assets of the company.
📋 Key Facts
- Total facility of $150M, split into four tranches: $50M funded immediately, $25M based on clinical/financing milestones (2027), $25M based on approval/sales milestones (2028), and $50M discretionary.
- Interest rate is the greater of 8.95% or prime + 2.20%, with maturity date of June 1, 2030.
- Lenders have the right to convert up to $15M of principal into common stock at $8.2526 per share.
- Collateral includes a first priority security interest in substantially all assets excluding intellectual property.
- Strict financial covenants: minimum unrestricted cash requirement (80% of obligations if market cap < $750M) starting April 1, 2027, and a minimum trailing 3-month net product revenue of $40M starting January 1, 2029.
- Chief Medical Officer Dr. Milos Miljkovic resigned effective May 31, 2026.
Cartesian Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made through a press release furnished with the SEC filing.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The announcement was made on April 30, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Carsten Brunn, Ph.D., serves as the President, CEO, and Chairman of the Board.
Dr. Murat Kalayoglu notified Cartesian Therapeutics of his resignation from the Board of Directors, effective March 31, 2026. He served as the Chairman of the Science and Technology Committee and his departure is reportedly not due to any disagreements with the company.
📋 Key Facts
- Dr. Murat Kalayoglu resigned from the Board of Directors effective March 31, 2026.
- Kalayoglu served as Chairman of the Science and Technology Committee and as a member of the Nominating and Corporate Governance Committee.
- The company stated the resignation was to 'pursue other opportunities' and not the result of any disagreement regarding operations, policies, or practices.
- Dr. Kalayoglu had served on the Board since 2023.
Cartesian Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025. The filing serves as a standard disclosure to furnish the earnings press release to the SEC.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025, on March 9, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
- The information provided is furnished and not considered 'filed' for purposes of Section 18 of the Exchange Act.